

(12) International Application Status Report

Received at International Bureau: 04 March 2010 (04.03.2010)

Information valid as of: 06 August 2010 (06.08.2010)

Report generated on: 22 July 2019 (22.07.2019)

(10) Publication number:

WO2010/095663

(43) Publication date:

26 August 2010 (26.08.2010)

(26) Publication language:

Japanese (JA)

(21) Application Number:

PCT/JP2010/052374

(22) Filing Date:

17 February 2010 (17.02.2010)

(25) Filing language:

Japanese (JA)

(31) Priority number(s):

61/202,321 (US)

(31) Priority date(s):

18 February 2009 (18.02.2009)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

C07D 401/14 (2006.01); *A61K 31/454* (2006.01); *A61K 31/506* (2006.01); *A61K 31/519* (2006.01); *A61K 31/5377* (2006.01); *A61K 31/55* (2006.01); *A61P 1/00* (2006.01); *A61P 1/02* (2006.01); *A61P 1/04* (2006.01); *A61P 1/08* (2006.01); *A61P 1/12* (2006.01); *A61P 1/16* (2006.01); *A61P 1/18* (2006.01); *A61P 3/04* (2006.01); *A61P 3/06* (2006.01); *A61P 3/10* (2006.01); *A61P 7/00* (2006.01); *A61P 9/00* (2006.01); *A61P 9/04* (2006.01); *A61P 9/10* (2006.01); *A61P 9/12* (2006.01); *A61P 11/00* (2006.01); *A61P 13/10* (2006.01); *A61P 13/12* (2006.01); *A61P 15/00* (2006.01); *A61P 17/02* (2006.01); *A61P 17/06* (2006.01); *A61P 19/02* (2006.01); *A61P 19/06* (2006.01); *A61P 19/10* (2006.01); *A61P 21/04* (2006.01); *A61P 25/00* (2006.01); *A61P 25/02* (2006.01); *A61P 25/28* (2006.01); *A61P 27/02* (2006.01); *A61P 27/12* (2006.01); *A61P 27/16* (2006.01); *A61P 29/00* (2006.01); *A61P 31/00* (2006.01); *A61P 35/00* (2006.01); *A61P 35/02* (2006.01); *A61P 43/00* (2006.01); *C07D 405/14* (2006.01); *C07D 413/14* (2006.01); *C07D 487/04* (2006.01)

(71) Applicant(s):

TAKEDA PHARMACEUTICAL COMPANY LIMITED [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410045 (JP) (for all designated states except US)

RIKIMARU, Kentaro [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP) (for US only)

IMOTO, Hiroshi [JP/US]; #206, 1742 Sand Hill Road, Palo Alto, California 94304 (US) (for US only)

KAMAURA, Masahiro [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP) (for US only)

(72) Inventor(s):

RIKIMARU, Kentaro; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP)

IMOTO, Hiroshi; #206, 1742 Sand Hill Road, Palo Alto, California 94304 (US)

KAMAURA, Masahiro; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP)

(74) Agent(s):

TAKASHIMA, Hajime; Meiji Yasuda Seimei Osaka Midosuji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410044 (JP)

(54) Title (EN): FUSED HETEROCYCLIC RING COMPOUND

(54) Title (FR): COMPOSÉ À NOYAU HÉTÉROCYCLIQUE FUSIONNÉ

(54) Title (JA): 縮合複素環化合物

(57) Abstract:

(EN): Disclosed is a compound represented by formula (I) or a salt thereof, which has GPR 119 agonist action and excellent medicinal effects useful for prevention/treatment of diabetes, adiposis and the like. In the formula, P represents a substituted 6-membered aromatic ring; Q represents a (substituted) 6-membered aromatic ring; A¹ represents CR^{4a}R^{4b}, NR^{4c}, O, S, SO, SO₂

(wherein R^{4a} - R^{4c} each represents H or the like); L^1 represents a (substituted) C_{1-5} alkylene; L^2 represents a bond, a (substituted) C_{1-3} alkylene; L^3 and L^4 each represents a (substituted) C_{1-3} alkylene; R^1 represents H, X, CN, a (substituted) hydrocarbon, a (substituted) heterocyclic ring or a (substituted) OH, or alternatively combines with A^1 to form a (substituted) 4- to 8-membered (heterocyclic) ring; R^2 represents H, CN or a (substituted) hydrocarbon; and R^{3a} represents $-COSR^{A1}$ or a (substituted) 5- or 6-membered aromatic ring (wherein R^{A1} represents a (substituted) hydrocarbon or a (substituted) heterocyclic ring.)

(FR): L'invention concerne un composé représenté par la formule (I) ou un sel de ce composé, qui présente une action d'antagoniste GPR119 et des effets médicaux excellents utiles à la prévention/au traitement des diabètes, de l'adipose et des maladies similaires. Dans la formule, P représente un noyau aromatique substitué à 6 chaînons; Q représente un noyau aromatique (substitué) à 6 chaînons; A^1 représente un groupe $CR^{4a}R^{4b}$, NR^{4c} , O, S, SO ou SO_2 (où R^{4a} à R^{4c} représentent chacun un atome H ou un élément similaire); L^1 représente un groupe alkylène en C1 à C5 (substitué); L^2 représente un liaison, un groupe alkylène en C1 à C3 (substitué); L^3 et L^4 représentent chacun un groupe alkylène en C1 à C3 (substitué); R^1 représente un atome H, X, un groupe CN, un hydrocarbure (substitué), un noyau hétérocyclique (substitué) ou un groupe OH (substitué), ou se combine sinon à A^1 pour former un noyau (hétérocyclique) (substitué) à 4 à 8 chaînons; R^2 représente un atome H, un groupe CN ou un hydrocarbure (substitué); et R^{3a} représente $-COSR^{A1}$ ou un noyau aromatique (substitué) à 5 ou 6 chaînons (où R^{A1} représente un hydrocarbure (substitué) ou un noyau hétérocyclique (substitué)).

(JA): GPR119アゴニスト作用を有し、糖尿病、肥満症等の予防・治療に有用であり、かつ優れた薬効を有する、下記式(1)で表される化合物またはその塩。P:置換6員芳香環、Q:(置換)6員芳香環
 $A^1:CR^{4a}R^{4b}, NR^{4c}, O, S, SO, SO_2 \{R^{4a-4c}:H \text{ 等}\}$ $L^1:(置換)C_{1-5}$ アルキレン、 $L^2:$ 結合、(置換) C_{1-3} アルキレン、 $L^{3-4}:(置換)C_{1-3}$ アルキレン、 $R^1:H, X, CN, (置換)炭化水素, (置換)複素環, (置換)OH$ 又は A^1 と共に (置換)4-8員(複素)環、 $R^2:H, CN, (置換)炭化水素、R^{3a}:-COSR^{A1}, (置換)5-6$ 員芳香環 $\{R^{A1}:(置換)炭化水素, (置換)複素環\}$

International search report:

Received at International Bureau: 18 March 2010 (18.03.2010) [JP]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM